Twist Bioscience Posts Record Revenue in Q3, Beating Expectations
August 8, 2022
Trending News ☀️
Twist Bioscience Intrinsic Value – Twist Bioscience ($NASDAQ:TWST) posted record revenue in the third quarter, beating expectations. The company’s press release showed that its GAAP EPS for the quarter was -$1.08, beating analyst expectations by $0.23. It is not yet clear how this will affect Twist Bioscience’s market and earnings in the long term.
However, the company’s strong performance in the third quarter is a positive sign.
Market Reaction
Most news outlets have given mixed reviews following the announcement. On Friday, Twist Bioscience stock opened at $49.0 and closed at $52.8, soar by 12.7% from previous closing price of 46.8. This is good news for investors, as the company continues to grow despite mixed reviews.
VI Analysis – Twist Bioscience Intrinsic Value
Company’s fundamentals reflect its long term potential, below analysis on TWIST BIOSCIENCE are made simple by VI app. The intrinsic value of TWIST BIOSCIENCE share is around $85.87, calculated by VI Line. Now TWIST BIOSCIENCE stock is traded at $49.41, undervalued by 42.46%.
Summary
The company attributed the beat to strong demand for its products and services. The stock price rose 12.7% following the news. The company has been expanding its capabilities and product offerings, which has led to increased demand for its services. It has also been working on improving its manufacturing process, which has helped to improve margins.
